Pharmaceutical

Oncoinvent’s Radspherin has FDA fast-track status for ovarian cancer

Oncoinvent has received FDA fast track designation for its therapy, Radspherin, to treat peritoneal metastases from ovarian cancer.

Jun 26, 2024 - 04:00
Oncoinvent’s Radspherin has FDA fast-track status for ovarian cancer
Oncoinvent has received FDA fast track designation for its therapy, Radspherin, to treat peritoneal metastases from ovarian cancer.
Read the original article

Tags:

Previous Article

Merck KGaA abandons Phase III trial for $1.08bn head & neck cancer drug

Next Article

Novavax seeks EMA approval for updated JN.1 Covid-19 vaccine

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Studies cited in abortion pill case are retracted due to flaws and conflicts of interest

Studies cited in abortion pill case are retracted due t...

Feb 9, 2024

STAT+: FTC tells Illumina to divest Grail, boosting Icahn’s case

STAT+: FTC tells Illumina to divest Grail, boosting Ica...

Apr 3, 2023

STAT+: FDA approves Sage Therapeutics’ rapid-acting medication for postpartum depression but not major depression

STAT+: FDA approves Sage Therapeutics’ rapid-acting med...

Aug 5, 2023